The impact of new insights and revised practice guidelines on prescribing drugs in the treatment of Type 2 diabetes mellitus
Aims The aim of this study was to investigate the impact of new insights and revised guidelines on initial and follow‐up treatment with antihyperglycaemic drugs over the period 1998–2003. Methods The InterAction Database (IADB), which contains pharmacy dispensing data from 53 community pharmacies in...
Gespeichert in:
| Veröffentlicht in: | British journal of clinical pharmacology 2006-12, Vol.62 (6), p.660-665 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 665 |
|---|---|
| container_issue | 6 |
| container_start_page | 660 |
| container_title | British journal of clinical pharmacology |
| container_volume | 62 |
| creator | Lub, René Denig, Petra Van Den Berg, Paul B. Hoogenberg, Klaas De Jong‐van den Berg, Lolkje T. W. |
| description | Aims
The aim of this study was to investigate the impact of new insights and revised guidelines on initial and follow‐up treatment with antihyperglycaemic drugs over the period 1998–2003.
Methods
The InterAction Database (IADB), which contains pharmacy dispensing data from 53 community pharmacies in the Northern and Eastern part of the Netherlands, was used in this study. Prevalence and incidence rates of oral antihyperglycaemic drug use were calculated for each year. Follow‐up treatment was compared for two cohorts of initial users of oral antihyperglycaemic drugs, starting treatment either 1 year before or 1 year after guideline revision.
Results
The prevalence and incidence rate of oral antihyperglycaemic drug use increased over the study period from 1.8% to 2.4% (P |
| doi_str_mv | 10.1111/j.1365-2125.2006.02711.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1885194</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>19996789</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5331-9f4d12c64288e2fae613cb4bdd17e60e15202d46023fd109d045a89d7bf1f1113</originalsourceid><addsrcrecordid>eNqNkU1v1DAQhiMEokvhLyBf4JbgsWMnOYAEK76kSnBYzpZjT7Je5Qs7absSPx6nu2rhBL7Y8jzvq5l5k4QAzSCeN4cMuBQpAyYyRqnMKCsAsttHyea-8DjZUE5lKpiAi-RZCAdKgYMUT5MLkEUlC0o3ya_dHonrJ21mMjZkwBvihuDa_RyIHizxeO0CWjL5SDiDpF2cxc4NGMg4xG8MxrvaDS2xfmlDVJM5Ws4e9dzjcOe6O05IGLFO1zhHYY9d5-YlPE-eNLoL-OJ8XyY_Pn3cbb-kV98-f92-v0qN4BzSqsktMCNzVpbIGo0SuKnz2looUFIEwSizuaSMNxZoZWkudFnZom6gievil8m7k--01D1aE9vyulOTd732RzVqp_6uDG6v2vFaQVkKqPJo8Pps4MefC4ZZ9S6YOIUecFyCkiVIyST_JwhVFRdfVhEsT6DxYwgem_tugKo1Y3VQa5RqjVKtGau7jNVtlL78c5oH4TnUCLw6AzoY3TVeD8aFB65kZVEUInJvT9yN6_D43w2oD9vv64v_Bv7lxF4</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>19996789</pqid></control><display><type>article</type><title>The impact of new insights and revised practice guidelines on prescribing drugs in the treatment of Type 2 diabetes mellitus</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wiley Free Content</source><source>Alma/SFX Local Collection</source><creator>Lub, René ; Denig, Petra ; Van Den Berg, Paul B. ; Hoogenberg, Klaas ; De Jong‐van den Berg, Lolkje T. W.</creator><creatorcontrib>Lub, René ; Denig, Petra ; Van Den Berg, Paul B. ; Hoogenberg, Klaas ; De Jong‐van den Berg, Lolkje T. W.</creatorcontrib><description>Aims
The aim of this study was to investigate the impact of new insights and revised guidelines on initial and follow‐up treatment with antihyperglycaemic drugs over the period 1998–2003.
Methods
The InterAction Database (IADB), which contains pharmacy dispensing data from 53 community pharmacies in the Northern and Eastern part of the Netherlands, was used in this study. Prevalence and incidence rates of oral antihyperglycaemic drug use were calculated for each year. Follow‐up treatment was compared for two cohorts of initial users of oral antihyperglycaemic drugs, starting treatment either 1 year before or 1 year after guideline revision.
Results
The prevalence and incidence rate of oral antihyperglycaemic drug use increased over the study period from 1.8% to 2.4% (P < 0.001) and 0.3% to 0.4% (P = 0.04). The proportion of metformin as initial treatment increased rapidly in the observation period from 14% to 50% (P < 0.001). Initial users of metformin in 2000 received additional treatment with a sulphonylurea in the follow‐up period less often compared with those who started metformin in 1998 (46%vs. 60%, P < 0.004). In contrast, initial users of sulphonylurea in 2000 received additional treatment with metformin more often compared with those who started a sulphonylurea in 1998 (42%vs. 36%, P < 0.008). The new drugs, thiazolidinediones and meglitinides, were seldom used as initial treatment
Conclusions
New insights and the revision of the practice guideline were followed by a significant increase in both initial and follow‐up treatment with metformin among patients with Type 2 diabetes mellitus.</description><identifier>ISSN: 0306-5251</identifier><identifier>EISSN: 1365-2125</identifier><identifier>DOI: 10.1111/j.1365-2125.2006.02711.x</identifier><identifier>PMID: 16796700</identifier><identifier>CODEN: BCPHBM</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Adolescent ; Adult ; Aged ; Aged, 80 and over ; Biological and medical sciences ; diabetes ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes. Impaired glucose tolerance ; Drug Prescriptions - statistics & numerical data ; Drug Utilization - statistics & numerical data ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Female ; guidelines ; Humans ; Hypoglycemic Agents - therapeutic use ; Male ; Medical sciences ; metformin ; Middle Aged ; Netherlands ; Pharmacology. Drug treatments ; Practice Guidelines as Topic ; Practice Patterns, Physicians' - statistics & numerical data ; Practice Patterns, Physicians' - trends ; Prescribing & Education</subject><ispartof>British journal of clinical pharmacology, 2006-12, Vol.62 (6), p.660-665</ispartof><rights>2007 INIST-CNRS</rights><rights>2006 The Authors Journal compilation © 2006 Blackwell Publishing Ltd 2006</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5331-9f4d12c64288e2fae613cb4bdd17e60e15202d46023fd109d045a89d7bf1f1113</citedby><cites>FETCH-LOGICAL-c5331-9f4d12c64288e2fae613cb4bdd17e60e15202d46023fd109d045a89d7bf1f1113</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1365-2125.2006.02711.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1365-2125.2006.02711.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,777,781,882,1412,1428,27905,27906,45555,45556,46390,46814</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18287775$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16796700$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lub, René</creatorcontrib><creatorcontrib>Denig, Petra</creatorcontrib><creatorcontrib>Van Den Berg, Paul B.</creatorcontrib><creatorcontrib>Hoogenberg, Klaas</creatorcontrib><creatorcontrib>De Jong‐van den Berg, Lolkje T. W.</creatorcontrib><title>The impact of new insights and revised practice guidelines on prescribing drugs in the treatment of Type 2 diabetes mellitus</title><title>British journal of clinical pharmacology</title><addtitle>Br J Clin Pharmacol</addtitle><description>Aims
The aim of this study was to investigate the impact of new insights and revised guidelines on initial and follow‐up treatment with antihyperglycaemic drugs over the period 1998–2003.
Methods
The InterAction Database (IADB), which contains pharmacy dispensing data from 53 community pharmacies in the Northern and Eastern part of the Netherlands, was used in this study. Prevalence and incidence rates of oral antihyperglycaemic drug use were calculated for each year. Follow‐up treatment was compared for two cohorts of initial users of oral antihyperglycaemic drugs, starting treatment either 1 year before or 1 year after guideline revision.
Results
The prevalence and incidence rate of oral antihyperglycaemic drug use increased over the study period from 1.8% to 2.4% (P < 0.001) and 0.3% to 0.4% (P = 0.04). The proportion of metformin as initial treatment increased rapidly in the observation period from 14% to 50% (P < 0.001). Initial users of metformin in 2000 received additional treatment with a sulphonylurea in the follow‐up period less often compared with those who started metformin in 1998 (46%vs. 60%, P < 0.004). In contrast, initial users of sulphonylurea in 2000 received additional treatment with metformin more often compared with those who started a sulphonylurea in 1998 (42%vs. 36%, P < 0.008). The new drugs, thiazolidinediones and meglitinides, were seldom used as initial treatment
Conclusions
New insights and the revision of the practice guideline were followed by a significant increase in both initial and follow‐up treatment with metformin among patients with Type 2 diabetes mellitus.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Biological and medical sciences</subject><subject>diabetes</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Drug Prescriptions - statistics & numerical data</subject><subject>Drug Utilization - statistics & numerical data</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>Etiopathogenesis. Screening. Investigations. Target tissue resistance</subject><subject>Female</subject><subject>guidelines</subject><subject>Humans</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Male</subject><subject>Medical sciences</subject><subject>metformin</subject><subject>Middle Aged</subject><subject>Netherlands</subject><subject>Pharmacology. Drug treatments</subject><subject>Practice Guidelines as Topic</subject><subject>Practice Patterns, Physicians' - statistics & numerical data</subject><subject>Practice Patterns, Physicians' - trends</subject><subject>Prescribing & Education</subject><issn>0306-5251</issn><issn>1365-2125</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkU1v1DAQhiMEokvhLyBf4JbgsWMnOYAEK76kSnBYzpZjT7Je5Qs7absSPx6nu2rhBL7Y8jzvq5l5k4QAzSCeN4cMuBQpAyYyRqnMKCsAsttHyea-8DjZUE5lKpiAi-RZCAdKgYMUT5MLkEUlC0o3ya_dHonrJ21mMjZkwBvihuDa_RyIHizxeO0CWjL5SDiDpF2cxc4NGMg4xG8MxrvaDS2xfmlDVJM5Ws4e9dzjcOe6O05IGLFO1zhHYY9d5-YlPE-eNLoL-OJ8XyY_Pn3cbb-kV98-f92-v0qN4BzSqsktMCNzVpbIGo0SuKnz2looUFIEwSizuaSMNxZoZWkudFnZom6gievil8m7k--01D1aE9vyulOTd732RzVqp_6uDG6v2vFaQVkKqPJo8Pps4MefC4ZZ9S6YOIUecFyCkiVIyST_JwhVFRdfVhEsT6DxYwgem_tugKo1Y3VQa5RqjVKtGau7jNVtlL78c5oH4TnUCLw6AzoY3TVeD8aFB65kZVEUInJvT9yN6_D43w2oD9vv64v_Bv7lxF4</recordid><startdate>200612</startdate><enddate>200612</enddate><creator>Lub, René</creator><creator>Denig, Petra</creator><creator>Van Den Berg, Paul B.</creator><creator>Hoogenberg, Klaas</creator><creator>De Jong‐van den Berg, Lolkje T. W.</creator><general>Blackwell Publishing Ltd</general><general>Blackwell Science</general><general>Blackwell Science Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>200612</creationdate><title>The impact of new insights and revised practice guidelines on prescribing drugs in the treatment of Type 2 diabetes mellitus</title><author>Lub, René ; Denig, Petra ; Van Den Berg, Paul B. ; Hoogenberg, Klaas ; De Jong‐van den Berg, Lolkje T. W.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5331-9f4d12c64288e2fae613cb4bdd17e60e15202d46023fd109d045a89d7bf1f1113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Biological and medical sciences</topic><topic>diabetes</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Drug Prescriptions - statistics & numerical data</topic><topic>Drug Utilization - statistics & numerical data</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>Etiopathogenesis. Screening. Investigations. Target tissue resistance</topic><topic>Female</topic><topic>guidelines</topic><topic>Humans</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Male</topic><topic>Medical sciences</topic><topic>metformin</topic><topic>Middle Aged</topic><topic>Netherlands</topic><topic>Pharmacology. Drug treatments</topic><topic>Practice Guidelines as Topic</topic><topic>Practice Patterns, Physicians' - statistics & numerical data</topic><topic>Practice Patterns, Physicians' - trends</topic><topic>Prescribing & Education</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lub, René</creatorcontrib><creatorcontrib>Denig, Petra</creatorcontrib><creatorcontrib>Van Den Berg, Paul B.</creatorcontrib><creatorcontrib>Hoogenberg, Klaas</creatorcontrib><creatorcontrib>De Jong‐van den Berg, Lolkje T. W.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of clinical pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lub, René</au><au>Denig, Petra</au><au>Van Den Berg, Paul B.</au><au>Hoogenberg, Klaas</au><au>De Jong‐van den Berg, Lolkje T. W.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The impact of new insights and revised practice guidelines on prescribing drugs in the treatment of Type 2 diabetes mellitus</atitle><jtitle>British journal of clinical pharmacology</jtitle><addtitle>Br J Clin Pharmacol</addtitle><date>2006-12</date><risdate>2006</risdate><volume>62</volume><issue>6</issue><spage>660</spage><epage>665</epage><pages>660-665</pages><issn>0306-5251</issn><eissn>1365-2125</eissn><coden>BCPHBM</coden><abstract>Aims
The aim of this study was to investigate the impact of new insights and revised guidelines on initial and follow‐up treatment with antihyperglycaemic drugs over the period 1998–2003.
Methods
The InterAction Database (IADB), which contains pharmacy dispensing data from 53 community pharmacies in the Northern and Eastern part of the Netherlands, was used in this study. Prevalence and incidence rates of oral antihyperglycaemic drug use were calculated for each year. Follow‐up treatment was compared for two cohorts of initial users of oral antihyperglycaemic drugs, starting treatment either 1 year before or 1 year after guideline revision.
Results
The prevalence and incidence rate of oral antihyperglycaemic drug use increased over the study period from 1.8% to 2.4% (P < 0.001) and 0.3% to 0.4% (P = 0.04). The proportion of metformin as initial treatment increased rapidly in the observation period from 14% to 50% (P < 0.001). Initial users of metformin in 2000 received additional treatment with a sulphonylurea in the follow‐up period less often compared with those who started metformin in 1998 (46%vs. 60%, P < 0.004). In contrast, initial users of sulphonylurea in 2000 received additional treatment with metformin more often compared with those who started a sulphonylurea in 1998 (42%vs. 36%, P < 0.008). The new drugs, thiazolidinediones and meglitinides, were seldom used as initial treatment
Conclusions
New insights and the revision of the practice guideline were followed by a significant increase in both initial and follow‐up treatment with metformin among patients with Type 2 diabetes mellitus.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>16796700</pmid><doi>10.1111/j.1365-2125.2006.02711.x</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0306-5251 |
| ispartof | British journal of clinical pharmacology, 2006-12, Vol.62 (6), p.660-665 |
| issn | 0306-5251 1365-2125 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_1885194 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wiley Free Content; Alma/SFX Local Collection |
| subjects | Adolescent Adult Aged Aged, 80 and over Biological and medical sciences diabetes Diabetes Mellitus, Type 2 - drug therapy Diabetes. Impaired glucose tolerance Drug Prescriptions - statistics & numerical data Drug Utilization - statistics & numerical data Endocrine pancreas. Apud cells (diseases) Endocrinopathies Etiopathogenesis. Screening. Investigations. Target tissue resistance Female guidelines Humans Hypoglycemic Agents - therapeutic use Male Medical sciences metformin Middle Aged Netherlands Pharmacology. Drug treatments Practice Guidelines as Topic Practice Patterns, Physicians' - statistics & numerical data Practice Patterns, Physicians' - trends Prescribing & Education |
| title | The impact of new insights and revised practice guidelines on prescribing drugs in the treatment of Type 2 diabetes mellitus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T05%3A29%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20impact%20of%20new%20insights%20and%20revised%20practice%20guidelines%20on%20prescribing%20drugs%20in%20the%20treatment%20of%20Type%202%20diabetes%20mellitus&rft.jtitle=British%20journal%20of%20clinical%20pharmacology&rft.au=Lub,%20Ren%C3%A9&rft.date=2006-12&rft.volume=62&rft.issue=6&rft.spage=660&rft.epage=665&rft.pages=660-665&rft.issn=0306-5251&rft.eissn=1365-2125&rft.coden=BCPHBM&rft_id=info:doi/10.1111/j.1365-2125.2006.02711.x&rft_dat=%3Cproquest_pubme%3E19996789%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=19996789&rft_id=info:pmid/16796700&rfr_iscdi=true |